Landmark agreement marks Taiwan’s entrance to western veterinary medical market
Taiwan News
Date: 2018/01/17
By: Renée Salmonsen, Taiwan News, Staff Writer
TAIPEI (Taiwan News) — The Taiwan-based drug development company, Lumosa
A new pain relief drug for dogs and cats is soon to enter western markets. (Photo: Pixabay)
Therapeutics, announced yesterday on their website that a licensing agreement with Skyline Vet Pharma (SVP), an American animal health product development company, has been signed for an animal pain management drug to enter specified western markets.
The new drug is “an extended-release analgesic injection for pain management in companion animals,” according to the Lumosa website. The new drug is a combination of nabuphine, a kappa-agonist, and partial mu-agonist aimed at relieving moderate to severe pain in cats and dogs as well as other pets.
Under this agreement the drug, currently referred to as CS011 and soon to be SVP-161, will be further developed, commercialized, and marketed exclusively by SVP for resale in the United States, Canada, Australia, and New Zealand. SVP will continue the necessary animal clinical studies needed to fulfill all regulations. [FULL STORY]
